دورية أكاديمية
Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
| العنوان: | Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. |
|---|---|
| المؤلفون: | Schlemmer, M., Wendtner, C.M., Falk, M., Abdel-Rahman, S., Licht, T., Baumert, J.J., Straka, C., Hentrich, M., Salat, C., Hiddemann, W., Issels, R.D. |
| المصدر: | Oncology 71, 32-39 (2006) |
| بيانات النشر: | Karger |
| سنة النشر: | 2006 |
| المجموعة: | PuSH - Publikationsserver des Helmholtz Zentrums München |
| مصطلحات موضوعية: | high-dose chemotherapy, Metastasis, Soft tissue sarcoma |
| الوصف: | Prognosis of patients with metastatic soft tissue sarcomas (MSTS) is poor even after response to doxorubicin-based chemotherapy. We report phase II data of high-dose chemotherapy and peripheral blood stem cell (PBSC) rescue in patients with MSTS responding to AI-G chemotherapy. PATIENTS AND METHODS: From 1997 to 2002, 55 patients with MSTS were prospectively treated with 4 cycles of AI-G (doxorubicin 75 mg/m(2), ifosfamide 6 g/m(2) with G-CSF support). Responders received 2 further cycles of AI-G with collection of PBSCs. High-dose chemotherapy consisted of ifosfamide 12 g/m(2), carboplatin 1.2 g/m(2) and etoposide 1.2 g/m(2) (HD-ICE) followed by reinfusion of PBSCs. RESULTS: Twenty-one of 55 patients (38%) were assessed as responders (3 complete response, 18 partial response). All but 2 patients refusing treatment received high-dose chemotherapy with PBSC rescue leading to grade IV hematologic toxicity without severe infections in all patients. No toxic death occurred. After a median follow-up time of 30 months, the median progression-free time was 12 months and survival time was 22 months for the entire group. By intent-to-treat analysis the probability of 5-year progression-free survival was significantly higher for patients allocated to HD-ICE compared to patients receiving second-line chemotherapy after failure of AI-G (14 vs. 3%; p = 0.003). The estimated 5-year overall survival between the 2 groups was different (27% vs. not reached) but did not reach significance (p = 0.08). CONCLUSION: HD-ICE is feasible and promising in patients with chemosensitive MSTS. A randomized phase III trial is warranted to further define the role of HD-ICE as consolidation treatment in these patients. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0030-2414 1423-0232 |
| العلاقة: | info:eu-repo/semantics/altIdentifier/wos/undefined; info:eu-repo/semantics/altIdentifier/isbn/0030-2414; info:eu-repo/semantics/altIdentifier/pissn/0030-2414; info:eu-repo/semantics/altIdentifier/ei; https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=4585Test; urn:isbn:0030-2414; urn:issn:0030-2414; urn:issn:1423-0232 |
| DOI: | 10.1159/000100447 |
| الإتاحة: | https://doi.org/10.1159/000100447Test https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=4585Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.470A0D72 |
| قاعدة البيانات: | BASE |
| تدمد: | 00302414 14230232 |
|---|---|
| DOI: | 10.1159/000100447 |